- Details
- Gwenaëlle Gravis joins Alicia Morgans in a discussion on the PEACE-1 phase 3 trial 8-month PSA outcomes of men with metastatic castration-sensitive prostate cancer (mCSPC). In the PEACE-1 study, investigators evaluated the efficacy and safety of abiraterone plus prednisone, with or without radiotherapy, in addition to standard of care in de novo mCSPC. The 8-month PSA decline to undetectable level...
|
- Details
- Alicia Morgans and Karim Fizazi discuss quality of life and patient-relevant endpoints with darolutamide in the phase 3 ARASENS study and which patient populations benefit most from this data. Dr Fizazi also details the P6 platform. P6 is for all patients with metastatic castration-sensitive disease. There are different phase three trials called P6. Drs Morgans and Fizazi discuss the P6 vulnerable...
|
- Details
- Alicia Morgans speaks with Felix Feng about his pioneering work in prostate cancer, specifically focusing on the integration of artificial intelligence (AI) to enhance understanding of pathology. Dr. Feng emphasizes that AI technology is already here and is being utilized to leverage extensive information about prostate cancer to make better-personalized decisions regarding patient care. He highli...
|
- Details
- Alicia Morgans speaks with Oliver Sartor about the SPLASH trial and advances in radioligand therapy. The SPLASH trial involves PSMA I&T Lutetium-177 (renamed PNT2002) for pre-chemo, metastatic CRPC patients, with some differences in dose and schedule compared to PSMA 617. In the lead-in study involving 27 PSMA PET-selected patients, the initial PSA 50 response rate was 40%, and the radiographic re...
|
- Details
- Alicia Morgans and Naomi Haas discuss the PROSPER Trial, focusing on the study design, results, and insights into kidney cancer treatment. The trial began from a collaboration at the Prostate Cancer Foundation meeting, leading to a two-arm study of 804 patients, exploring the effects of nivolumab preoperatively followed by surgery and adjuvant therapy, versus surgery alone. Unfortunately, the prim...
|
- Details
- Marina Parry and Gerhardt Attard join Alicia Morgans in discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for metastatic hormone-sensitive prostate cancer (mHSPC) starting ADT: overall survival (OS) results of 2 randomized Phase III trials from the STAMPEDE pr...
|
- Details
- Alicia Morgans is joined by Neal Shore, who provides his perspective on the phase 3 ARASENS data for patients with metastatic hormone-sensitive prostate cancer, which demonstrates the superiority in terms of survival and numerous other secondary endpoints of triplet versus doublet therapy. In ARASENS, darolutamide + androgen-deprivation therapy (ADT) + docetaxel significantly reduced risk of death...
|
- Details
- Alicia Morgans speaks with Toni Choueiri about groundbreaking developments in the treatment of kidney cancer, particularly through the LITESPARK program. Dr. Choueiri outlines the successful integration of HIF-2α inhibitors like belzutifan into kidney cancer therapeutics, emphasizing the drug's promising durability and lack of new toxicities. The conversation pivots around the significance of the...
|
- Details
- In this brief commentary, Charles Ryan highlights the phase 3, open-label PRESTO study, its importance, and its uniqueness being the first phase 3 study in serologic relapse prostate cancer with a positive result. Many of these patients with serologic relapse are destined to experience metastatic disease, castration-resistant prostate cancer, and death from the disease. The PRESTO study or the (AF...
|
- Details
- In this conversation, Rahul and Charles Ryan discuss the AFT-19, PRESTO study of androgen annihilation in high-risk biochemically relapsed prostate cancer. PRESTO is looking at a finite duration of treatment for patients with a rising PSA after prior surgery in the biochemically recurrent, hormone-sensitive setting. There were three treatment arms. The standard of care was ADT monotherapy, the exp...
|
